Physician profile
Eduardo Guzman
NPI 1295780005
$1,589.16
in general payments reported to CMS, 2019-2025
16 companies · $96.49 in 2025
The $96.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $271 · 2021: $35.52 · 2022: $125 · 2023: $165 · 2024: $135 · 2025: $96.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $465.57 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $241.93 | 2019-2025 | Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $198.21 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $191.89 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Bard Peripheral Vascular, INC. | $136.98 | 2019 | |
| Amarin Pharma, INC. | $101.12 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $50.00 | 2022 | |
| Pfizer INC. | $47.74 | 2020-2025 | |
| Exact Sciences Corporation | $44.39 | 2023-2024 | Cologuard Collection Kit |
| Nevro Corp. | $25.13 | 2024 | Senza |
| Astellas Pharma US INC | $17.61 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $16.35 | 2019 | |
| Amgen INC. | $15.08 | 2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $14.68 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.78 | 2025 | Zoryve |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $8.70 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.